Contact
Please use this form to send email to PR contact of this press release:
Paras Biopharma Successfully Develops Cytofold StructQuant® Tech for Cytoplasmic Disulphide Formation
TO:
Mark Jackson
Paras Biopharmaceuticals Finland Oy
+358442905993